April 2015—Agendia received 510(k) clearance from the Food and Drug Administration for its MammaPrint breast cancer recurrence test in formalin-fixed, paraffin-embedded tissue.
Read More »Home >> Tag Archives: Agendia
Molecular subtyping with Agendia tests, 6/14
June 2014—Research presented at the annual conference of the American Society of Breast Surgeons in May reported that molecular subtyping using Agendia’s MammaPrint and BluePrint tests can provide guidance about whether to propose neoadjuvant treatment and what kind of treatment to recommend.
Read More »